The obesity drug liraglutide cut migraine days in half in a small trial, though more research is needed to exclude the placebo effect, researchers said.

People with unresponsive chronic migraine and obesity experienced substantial relief after they started taking a GLP-1 drug, ...

Migraines are a common ailment worldwide, affecting nearly 15% of the global population. At times, they can be debilitating ...

A GLP-1 drug led to fewer days with headaches, a small pilot study of migraine sufferers shows. It may work by lowering pressure inside the head.

MR is associated with better treatment response than gepants in patients with migraine who previously had an inadequate response to gepants.

Patients with migraine discontinued treatment less often with atogepant and experienced a greater reduction in mean monthly migraine days compared with topiramate, according to topline results from a ...

More than 37 million people in the United States suffer from migraines. If you’re one of them, you know they can be triggered ...

A 75% plus increase in good days/month with eptinezumab is associated with improved migraine symptoms, brain fog, and overall well-being in chronic migraine.

Although anti-calcitonin gene-related peptides are safe and efficacious for adolescents with chronic migraine, access to ...

Migraine treatment with topiramate is linked to lower risks of end-stage kidney disease (ESKD), death, and ventricular arrhythmia/cardiac arrest, an investigator reported at the 62 nd European Renal ...

Migraines are one of the top ten most debilitating illnesses. That is according to the World Health Organization. They are ...

Atogepant 60 mg once daily leads to meaningful weight loss in patients with overweight or obesity receiving preventive ...